These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23856051)

  • 1. Are hERG channel blockers also phospholipidosis inducers?
    Sun H; Xia M; Shahane SA; Jadhav A; Austin CP; Huang R
    Bioorg Med Chem Lett; 2013 Aug; 23(16):4587-90. PubMed ID: 23856051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why are most phospholipidosis inducers also hERG blockers?
    Slavov S; Stoyanova-Slavova I; Li S; Zhao J; Huang R; Xia M; Beger R
    Arch Toxicol; 2017 Dec; 91(12):3885-3895. PubMed ID: 28551711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers.
    Aronov AM
    J Med Chem; 2006 Nov; 49(23):6917-21. PubMed ID: 17154521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacophore modeling for hERG channel facilitation.
    Yamakawa Y; Furutani K; Inanobe A; Ohno Y; Kurachi Y
    Biochem Biophys Res Commun; 2012 Feb; 418(1):161-6. PubMed ID: 22244872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel hypothesis for the binding mode of HERG channel blockers.
    Choe H; Nah KH; Lee SN; Lee HS; Lee HS; Jo SH; Leem CH; Jang YJ
    Biochem Biophys Res Commun; 2006 May; 344(1):72-8. PubMed ID: 16616004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
    Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
    J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.
    Roth GJ; Heckel A; Kley JT; Lehmann T; Müller SG; Oost T; Rudolf K; Arndt K; Budzinski R; Lenter M; Lotz RR; Schindler M; Thomas L; Stenkamp D
    Bioorg Med Chem Lett; 2015 Aug; 25(16):3270-4. PubMed ID: 26077492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A critical assessment of combined ligand- and structure-based approaches to HERG channel blocker modeling.
    Du-Cuny L; Chen L; Zhang S
    J Chem Inf Model; 2011 Nov; 51(11):2948-60. PubMed ID: 21902220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and biological evaluation of novel somatostatin receptor subtype-2 agonists: Optimization for potency and risk mitigation of hERG and phospholipidosis.
    Ishida A; Okabe Y; Matsushita T; Sekiguchi T; Nishio T; Komagata T; Iwaki M; Miyata H; Katagi J; Naganawa A; Maruyama T; Imagawa A
    Bioorg Med Chem; 2021 Nov; 49():116424. PubMed ID: 34626901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel.
    Ekins S; Crumb WJ; Sarazan RD; Wikel JH; Wrighton SA
    J Pharmacol Exp Ther; 2002 May; 301(2):427-34. PubMed ID: 11961040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human ether-a-go-go-related gene channel blockers and its structural analysis for drug design.
    Narayana Moorthy NS; Ramos MJ; Fernandes PA
    Curr Drug Targets; 2013 Jan; 14(1):102-13. PubMed ID: 23061466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment of an in silico phospholipidosis prediction method using descriptors related to molecular interactions causing phospholipid-compound complex formation.
    Haranosono Y; Nemoto S; Kurata M; Sakaki H
    J Toxicol Sci; 2016 Apr; 41(2):321-8. PubMed ID: 26961617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D-SDAR modeling of hERG potassium channel affinity: A case study in model design and toxicophore identification.
    Stoyanova-Slavova IB; Slavov SH; Buzatu DA; Beger RD; Wilkes JG
    J Mol Graph Model; 2017 Mar; 72():246-255. PubMed ID: 28129595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis.
    Crumb WJ; Ekins S; Sarazan RD; Wikel JH; Wrighton SA; Carlson C; Beasley CM
    Pharm Res; 2006 Jun; 23(6):1133-43. PubMed ID: 16715368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive QSAR models development and validation for human ether-a-go-go related gene (hERG) blockers using newer tools.
    Moorthy NS; Ramos MJ; Fernandes PA
    J Enzyme Inhib Med Chem; 2014 Jun; 29(3):317-24. PubMed ID: 23560722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of phospholipidosis induction: a cell-based assay in high-throughput and high-content format.
    Shahane SA; Huang R; Gerhold D; Baxa U; Austin CP; Xia M
    J Biomol Screen; 2014 Jan; 19(1):66-76. PubMed ID: 24003057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channels.
    Xia M; Shahane SA; Huang R; Titus SA; Shum E; Zhao Y; Southall N; Zheng W; Witt KL; Tice RR; Austin CP
    Toxicol Appl Pharmacol; 2011 May; 252(3):250-8. PubMed ID: 21362439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent developments in computational prediction of HERG blockage.
    Wang S; Li Y; Xu L; Li D; Hou T
    Curr Top Med Chem; 2013; 13(11):1317-26. PubMed ID: 23675938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effects of liensinine and neferine on the human ether-a-go-go-related gene potassium channel and pharmacological activity analysis.
    Dong ZX; Zhao X; Gu DF; Shi YQ; Zhang J; Hu XX; Hu MQ; Yang BF; Li BX
    Cell Physiol Biochem; 2012; 29(3-4):431-42. PubMed ID: 22508050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds.
    Hanumegowda UM; Wenke G; Regueiro-Ren A; Yordanova R; Corradi JP; Adams SP
    Chem Res Toxicol; 2010 Apr; 23(4):749-55. PubMed ID: 20356072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.